This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
… and presented positive pre-clinical data at two European scientific conferences. WINGS, a Phase 1/2 safety and … F508del mutation were presented at the North American CF conference. A Phase 2 study is currently being designed and …
